Montanide

PreclinicalSmall molecule

NNYU Langone Health

Montanide is one of 34 small molecule programs targeting Myeloid Neoplasm. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid NeoplasmActive, not recruiting

Myeloid NeoplasmPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Myeloid Neoplasm

#DrugCompanyPhaseTrials

PEGASYS

Ppharmaand GmbH

Phase 3

1 2

Cytosar

Teva

Phase 2

2 3

Novantrone

Pfizer

Phase 2

2 4

Cellcept

Roche

Phase 2

1 5

Fludara

Sanofi

Phase 2

1 6

Neoral

Novartis

Phase 2

1 7

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 8

Idhifa

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 9

Leustatin

EMD Serono

Phase 2

2 10

Alkeran

AApotex Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematologic Cancer1 trial

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Unknown status·BBenovus Bio, Inc.·Phase 1·NCT02240537·4 enrolled

Vaccination1 trial

Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors

Completed·NNYU Langone Health·Phase 1·NCT00935545·15 enrolled

Myeloid Neoplasm1 trial

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00665002·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Montanide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Montanide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Montanide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNYU Langone Health

Montanide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematologic Cancer1 trial

Vaccination1 trial

Myeloid Neoplasm1 trial

References

Drug Info

Quick Facts

Related News